Juno Therapeutics (JUNO) Shares are Down -11.84%

Juno Therapeutics (JUNO) : During the past 4 weeks, traders have been relatively bearish on Juno Therapeutics (JUNO), hence the stock is down -9.48% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.28% relative to the S&P 500. The 4-week change in the price of the stock is -9.6% and the stock has fallen -11.84% in the past 1 week.

The stock has recorded a 20-day Moving Average of 12.08% and the 50-Day Moving Average is 13.04%.The 200 Day SMA reached 26.22%. Juno Therapeutics Inc. has dropped 41.36% during the last 3-month period . Year-to-Date the stock performance stands at -35.32%.


Juno Therapeutics (NASDAQ:JUNO): The stock opened in the green at $29.33 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $29.45 and a low of $28.34 for the day. The stock did not find buyers even at the lows and closed at $28.44 recording a loss of -2.90%. 964,427 shares exchanged hands during the trading day. The stock had closed at $29.29 in the previous days trading.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.